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Afﬁnity maturationPreviously we reported a broadly HIV-1 neutralizing mini-antibody (Fab 3674) of modest potency that was
derived from a human non-immune phage library by panning against the chimeric gp41-derived construct
NCCG-gp41. This construct presents the N-heptad repeat of the gp41 ectodomain as a stable, helical, disulﬁde-
linked trimer that extends in helical phase from the six-helix bundle of gp41. In this paper, Fab 3674 was
subjected to afﬁnity maturation against the NCCG-gp41 antigen by targeted diversiﬁcation of the CDR-H2 loop
to generate a panel of Fabs with diverse neutralization activity. Three afﬁnity-matured Fabs selected for
further study, Fabs 8060, 8066 and 8068, showed signiﬁcant increases in both potency and breadth of
neutralization against HIV-1 pseudotyped with envelopes of primary isolates from the standard subtype B
and C HIV-1 reference panels. The parental Fab 3674 is 10–20-fold less potent in monovalent than bivalent
format over the entire B and C panels of HIV-1 pseudotypes. Of note is that the improved neutralization
activity of the afﬁnity-matured Fabs relative to the parental Fab 3674 was, on average, signiﬁcantly greater
for the Fabs in monovalent than bivalent format. This suggests that the increased avidity of the Fabs for the
target antigen in bivalent format can be partially offset by kinetic and/or steric advantages afforded by the
smaller monovalent Fabs. Indeed, the best afﬁnity-matured Fab (8066) in monovalent format (∼50 kDa) was
comparable in HIV-1 neutralization potency to the parental Fab 3674 in bivalent format (∼120 kDa) across
the subtype B and C reference panels.
Published by Elsevier Inc.Introduction
Fusion of the HIV-1 virus and host cell membranes is mediated by
the surface envelope (Env) glycoproteins gp120 and gp41 (Berger et
al., 1999; Eckert and Kim, 2001a). The binding of gp120 to the primary
receptor CD4 and the coreceptor CXCR4 triggers a series of
conformational changes in both gp120 and gp41 that lead to the
formation of a pre-hairpin intermediate (PHI) of the ectodomain of
gp41 (Furuta et al., 1998). In the PHI the C-heptad repeat (C-HR;
residues 623–663) and the helical coiled-coil trimer of the N-heptad
repeat (N-HR, residues 542–591) do not interact with one another but
bridge the viral and target cell membranes in an overall extended
conformation through the C- and N-termini of gp41, respectivelyInc.(Chan et al., 1998; Furuta et al., 1998; Eckert and Kim, 2001a; Gallo et
al., 2003; Melikyan et al., 2006). The subsequent formation of a six-
helix bundle (6-HB) with the N-HR trimer surrounded by three C-HR
helices (Chan et al., 1997; Tan et al., 1997; Weissenhorn et al., 1997;
Caffrey et al., 1998) brings the viral and target cell membranes into
contact eventually leading to fusion. The N-HR and C-HR in the PHI are
accessible and can therefore be targeted by gp41-directed fusion
inhibitors (Wild et al., 1992; Jiang et al., 1993;Wild et al., 1994; Eckert
et al., 1999; Louis et al., 2001; Root et al., 2001; Eckert and Kim, 2001b;
Bewley et al., 2002; Louis et al., 2003; Matthews et al., 2004; Root and
Steger, 2004; Eckert et al., 2008).
The conserved nature of the gp41 N-HR suggests that it may
represent an attractive target for generating antibodies with broadly
neutralizing activity. However, the majority of antibodies raised
against both the N-HR and 6-HB of gp41 have been only weakly
inhibitory or non-neutralizing (Jiang et al., 1998; Chen et al., 2000;
Golding et al., 2002; Louis et al., 2003), presumably because of the
Table 1
Afﬁnity of monovalent, afﬁnity-matured Fabs for the antigen NCCG-gp41 and
corresponding CDR-H2 sequences.
113E. Gustchina et al. / Virology 393 (2009) 112–119transient exposure of the N-HR trimer during the fusion process and
the large size of IgGs making access difﬁcult (Hamburger et al., 2005;
Steger and Root, 2006; Eckert et al., 2008). To date, six modestly
neutralizing antibodies directed against the N-HR have been reported:
Fab 3674 (Gustchina et al., 2007), D5 (Miller et al., 2005; Luftig et al.,
2006), 8K8 (Nelson et al., 2008), DN9 (Nelson et al., 2008), m46
(Choudhry et al., 2007) and m44 (Zhang et al., 2008).
In recent work (Louis et al., 2005; Gustchina et al., 2007) we made
use of a chimeric protein known as NCCG-gp41 (Louis et al., 2001)
which presents the N-HR as a stable, helical, disulﬁde-linked trimer
that extends in helical phase from the 6-HB core of gp41, to select
monoclonal antibodies by phage display from a synthetic human
combinatorial antibody library (HuCAL GOLD) comprising more than
1010 human speciﬁcities (Knappik et al., 2000; Kretzschmar and von
Ruden, 2002; Rothe et al., 2008). The HuCAL GOLD library includes
diversiﬁcation of all six complementarity determining regions (CDRs)
according to the sequence and length variability found in naturally
rearranged human antibodies (Rothe et al., 2008). Our initial attempts
resulted in a set of Fabs that inhibited Env-mediated cell fusion in a
vaccinia virus-based fusion assay but were non-neutralizing in an
Env-pseudotyped virus neutralization assay (Louis et al., 2005).
Subsequently, Fab 3674 with broad neutralizing activity against
HIV-1 pseudotyped with Envs from diverse laboratory-adapted B
strains of HIV-1 and primary isolates of subtypes A, B and C, were
isolated (Gustchina et al., 2007). Fab 3674 recognizes both the
internal timeric N-HR coiled-coil, and the 6-HB of gp41 (Gustchina et
al., 2007).
The D5 monoclonal antibody was derived from a naive scFv library
selected by panning against the gp41-derived construct 5-helix
(Miller et al., 2005; Luftig et al., 2006). 5-helix is a single chain
construct in which the N-HR trimer is surrounded by only 2 C-HR
helices, thereby exposing two of the three N-HR helices (Root et al.,
2001). There are a number of interesting differences between Fab
3674 and D5. While Fab 3674 and the C34 peptide (derived from the
C-HR and comprising residues 628–661 of gp41; (Chan and Kim,
1998)) neutralize HIV-1 either additively (Fab in monovalent format)
or synergistically (Fab in bivalent format) (Gustchina et al., 2007),
binding of D5 and C34 appears to be mutually exclusive (Miller et al.,
2005). 8K8 and DN9 (Nelson et al., 2008) monoclonal antibodies were
selected from rabbit (b9 rabbit immunized against N35CCG-N13) and
human (infected HIV-1 individual) phage display libraries, respec-
tively, by panning against the N-HR trimer mimetic N35CCG-N13
(Louis et al., 2003). In contrast to Fab 3674, 8K8 and DN9 are targeted
speciﬁcally to the N-HR trimeric coiled-coil and do not bind to the 6-
HB of gp41. m46 (Choudhry et al., 2007) and m44 (Zhang et al., 2008)
monoclonal antibodies were selected from a human immune phage
library by panning against gp140, a soluble form of the Env
ectodomain comprising uncleaved gp120 and gp41; m46 binds only
to 5-HB but not to 6-HB or the N-HR trimer, while m44 binds to 5-
helix and the 6-HB, but not to the N-HR trimer.
In this paper we set out to improve the potency of Fab 3674
(Gustchina et al., 2007) by afﬁnity maturation against the NCCG-gp41
antigen using targeted diversiﬁcation of the CDR-H2 loop. Due to their
unique modular structure HuCAL antibodies are ideal for the speciﬁc
optimization of CDRs (Knappik et al., 2000). Recently, an afﬁnity
improvement of 5000-fold was achieved by parallel CDR-L3 and CDR-
H2 diversiﬁcation and subsequent combination of optimized CDR-L3
and CDR-H2 antibodies (Steidl et al., 2008).
Afﬁnity maturation of the CDR-H2 of Fab 3674 resulted in the
generation of a panel of Fabs that displayed signiﬁcantly improved
afﬁnity towards the target antigen NCCG-gp41 and exhibited
diverse HIV-1 neutralizing activity. The three best Fabs displayed
enhanced HIV-1 neutralization properties relative to the original
Fab 3674, both in terms of IC50 values and neutralization breadth
over a standard panel of Envs from primary isolates of HIV-1
subtypes B and C.Results and discussion
Afﬁnity maturation of Fab 3674
The parental neutralizing Fab 3674 (Gustchina et al., 2007) was
derived from the synthetic human Fab library HuCAL Gold comprising
more than 1010 antibody genes (Knappik et al., 2000) by panning
against NCCG-gp41 (Louis et al., 2001), a construct that presents the N-
HR of gp41 as a stable helical, disulﬁde-linked trimer that extends in
helical phase from the 6-HB core. Fab 3674 was subjected to afﬁnity
maturation by diversiﬁcation of the heavy chain CDR-H2 loop.
Speciﬁcally, the original CDR-H2 sequence of the Fab 3674 gene was
replaced by a repertoire of CDR-H2 sequences designed according to
the respective amino acid distribution at each position of naturally
occurring, human rearranged antibody genes (Virnekas et al., 1994;
Knappik et al., 2000; Rothe et al., 2008). A total of 1.3×106 Fab genes
with different heavy chain CDR-H2 loops were generated in this
manner. After two rounds of panning against NCCG-gp41 coupled to
magnetic beads, applying increased washing stringency relative to
that used for the parental Fab 3674, the enriched pool of Fab genes
was subcloned into an expression vector. 368 clones were tested for
binding to NCCG-gp41 coupled beads, the 10 clones with the best
signal and an additional 10 clones selected at random were
sequenced, and 12 unique Fabs were found. The 10 Fabs with the
highest ELISA signal on NCCG-gp41 were selected for further
characterization and were expressed in both monovalent (mF) and
bivalent (bF) formats. The latter is obtained by the addition of a helix–
loop–helix dimerization domain to the C-terminus of the heavy chain
(Pluckthun, 1992).
Table 1 summarizes the CDR-H2 sequences together with the
equilibrium dissociation constants (KD) for the binding of Fab 3674
and the 10 afﬁnity-matured Fabs (in monovalent format) to NCCG-
gp41. The KD values, determined by solution equilibrium titration
using an electrochemiluminescence (ECL) based afﬁnity measure-
ment (Haenel et al., 2005; Steidl et al., 2008), range from 7 to 25 nM,
compared to ∼97 nM for the parental Fab 3674. Western blot analysis
against a panel of gp41 ectodomain-derived constructs comprising
NCCG-gp41, N35CCG-N13, N35CCG, 6-HB and 5-HB revealed the same
pattern of binding for all the Fabs, including the parental Fab 3674 (cf.
Fig. 2 of Gustchina et al. (2007)). Thus all the Fabs recognize the fully
exposed internal trimer of N-HR helices (cf. NCCG-g41, N34CCG,
N35CCG-N13), the (N-HR)3/C-HR3 six-helix bundle (cf. 6-HB and
NCCG-gp41), and a partially exposed trimer of N-HR helices (cf. 5-helix
in which two of the three N-HR helices are exposed) (Fig. 1A).
Likewise, the pattern of intensities observed for the single (Fig. 1B)
and double (Fig. 1B) alanine mutants of 6-HB comprising surface
exposed residues of the N-HR (Gustchina et al., 2007) is similar,
indicating that the parental and afﬁnity-matured Fabs bind to the
Fig. 1.Western blot analysis under non-reducing conditions of gp41-derived constructs reacting with the monovalent Fab mF-8066. (A) NCCG-gp41, N35CCG-N13, N34CCG, 6-HB and
5-helix. (B) Single and (C) double alanine scanningmutants of 6-HB involving solvent exposed N-HR residues that lie in the shallow groove between the two C-HR helices (Gustchina
et al., 2007). The molecular weights of trimeric NCCG-gp41 (35.4 kDa), N35CCG-N13 (22.6 kDa) and N34CCG (18 kDa) held together by disulﬁde bridges are indicated. 6-HB is a 10 kDa
popypeptide chain spanning the N-HR and C-HR that adopts a trimeric fold (comprising the minimal thermostable ectodomain core of gp41) during Western blotting upon transfer
of the protein from the gel to the nitrocellulose membrane. 5-helix is a single chain polypeptide of 25.4 kDa.
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that is surface exposed and lies between two C-HR helices of the 6-HB.
Neutralization activity of afﬁnity-matured Fabs against
laboratory-adapted strains of subtype B HIV-1
The neutralization activity of the parental Fab 3674 in monova-
lent format and the afﬁnity-matured monovalent Fabs against
diverse laboratory-adapted HIV-1 subtype B strains using an Env-
pseudotyped virus neutralization assay are reported in Table 2.
Examples of dose–response curves against diverse laboratory-
adapted HIV-1 subtype B strains for one of the Fabs, mF-8066, is
shown in Fig. 2A. As expected no neutralization activity is observed
for two negative control viruses pseudotyped with an amphotrophic
Env from Murine leukemia virus (MuLV) and vesicular stomatitis
virus (VSV) (Fig. 2B).
Surprisingly, not all of the Fabs with improved binding afﬁnity
towards the target NCCG-gp41 antigen showed HIV-1 neutralization
activity. This points to the importance of kinetic restriction and
suggests that the association and/or dissociation rate constants also
play a key role in determining neutralization activity (Steger and Root,
2006). Indeed, 4 Fabs (mF-8061, mF-8062, mF-8063 and mF-8065)
with KD values ranging from 17–25 nM showed no detectable
neutralization activity. By way of contrast, the parental mF-3674Table 2
Neutralization activity of afﬁnity-matured Fabs against HIV-1 subtype B laboratory-adapted
Antibody HIV-1 Env strain, IC50 (nM)a
HXB2 NL4-3 SF162
3674 630±160 480±220 2500±690
8059 400±89 98±26 3200±850
8060 130±30 36±7 1000±200
8061 NA NA NA
8062 NA NA NA
8063 NA NA NA
8064 790±270 270±140 5200±1800
8065 NA NA NA
8066 82±29 26±9 510±150
8068 160±72 34±11 1400±380
8069 880±300 360±210 NA
a NA, no activity. Neutralization activity was too weak to reliably determine an IC50.(KD∼97 nM) neutralized 6 out of 7 the strainswith IC50 values ranging
from ∼480 to ∼2100 nM. Of the 6 afﬁnity-matured Fabs that were
neutralizing, the KD values for binding to NCCG-gp41 were ≤15 nM,
but beyond that there was no apparent correlation between the actual
KD and IC50 values. For example, mF-8069 had the lowest KD value
(7 nM) of all the afﬁnity-matured Fabs but was comparable to or
slightly worse than the original mF-3674 in terms of HIV-1
neutralization activity. Three matured Fabs, 8060, 8066 and 8068,
however, displayed signiﬁcantly improved neutralization activity
relative to mF-3674 and were selected for further study. The best,
mF-8066, exhibited a 5–20-fold increase in HIV-1 neutralization
potency relative to mF-3674 for 6 out of the 7 HIV-1 strains; for the
seventh HIV-1 strain, 89.6, mF-8066 was neutralizing while mF-3674
was not.
A comparison of the CDR-H2 sequences shown in Table 1 in the
light of the neutralization results is of interest. Three (8061, 8062 and
8065) of the four non-neutralizing Fabs, have a substitution of Phe54
to a less bulky amino acid (Met, Ile and His, respectively). The fourth
non-neutralizing Fab (8063), as well as the poorly neutralizing Fab
8069 has a substitution to an aromatic residue (Phe and Trp,
respectively) at position 56. An aromatic residue at position 53 (cf.
Fabs 8064 and 8065) is also unfavorable. The three best Fabs, 8060,
8066 and 8068, all have an Ile or Leu at position 53, and a Ser or Thr at
position 56. The original Fab, 3674 also has an Ile at position 53, but astrains and primary isolates BaL01 and BaL26.
JR CSF 89.6 BaL01 BaL26
2100±600 NA 1100±270 1900±960
1500±470 1100±240 1100±310 970±420
620±380 500±130 360±120 360±130
NA NA NA NA
NA NA NA NA
NA NA NA NA
NA 1300±560 2300±1300 1100±520
NA NA NA NA
230±160 380±110 200±73 280±69
110±92 350±110 450±110 580±220
NA 660±400 NA 1900±760
Fig. 3. Antagonism of Fab mF-8066 and the NCCG-gp41 antigen observed in an HXB2
Env-pseudotyped HIV neutralization assay. IC50s were obtained from dose–response
curves measured for a range of ﬁxed molar combination ratios of mF 8066 and NCCG-
gp41. The IC50s for mF-8066 and NCCG-gp41 alone are 82±29 and 34±10 nM,
respectively. The KD for the binding of mF-8066 to NCCG-gp41 is 15 nM (Table 1).
Combination index (CI) values greater than 1 indicate that two inhibitors are mutually
antagonistic. Maximum antagonism is observed at a molar ratio of mF-8066 to NCCG-
gp41 of 3:1, as expected given that NCCG-gp41 is a symmetric trimer with three
symmetric binding sites for mF-8066.
Fig. 2. Dose–response curves for antiviral activity of the monovalent Fab mF-8066
against (A) diverse laboratory-adapted HIV-1 subtype B strains and (B) MuLV and VSV
(negative controls) in an Env-pseudotyped virus neutralization assay.
115E. Gustchina et al. / Virology 393 (2009) 112–119longer amino acid,Met, at position 56. One can therefore conclude that
residues at positions 53, 54 and 56, with an optimal sequence of Ile/
Leu, Phe and Ser/Thr, respectively, likelymake key contactswith gp41.
NCCG-gp41 and Fab mF-8066 are mutually antagonistic
To rule out any potential non-speciﬁc effects inherent in the Env-
pseudotyped HIV neutralization assay, we tested whether addition of
the target antigen, NCCG-gp41, in the assay could adsorb out the
neutralization activity of the most potent monovalent Fab mF-8066.
Since NCCG-gp41 was designed to bind to the C-HR of the PHI and is
itself a potent nanomolar inhibitor of HIV-1 fusion (Louis et al., 2001),
we tested the neutralizing activity of mixtures of mF-8066 and NCCG-
gp41 in various ﬁxed molar ratios ranging from 30:1 to 1:10, and
analyzed the combination effects using the method of Chou and
Talalay (1981, 1984) as described previously (Gustchina et al., 2006).
Since the NCCG-gp41 trimer has three symmetrically related binding
sites for Fab 8066, one would expect that maximum antagonism
between mF-8066 and NCCG-gp41 would be observed at a molar ratio
of 3:1. When an excess of either mF-8066 or NCCG-gp41 is present in
the mixture, one would predict that neutralization activity is
dominated by the inhibitor in excess. The dose reduction index
(DRI) of inhibitor x in combination with inhibitor y is given by DRIx=
(IC50)x/IC50)x,y, where (IC50)x and IC50)x,y are the IC50 of x alone and in
combination with y, respectively. The combination index (CI) which
describes the summation of the effects of the two inhibitors is given
by CI=(DRIx)−1+(DRIy)−1+(DRIxDRIy)−1 (Chou and Talalay,
1984; Gustchina et al., 2006). CI values equal to, greater than, or
less than 1 are indicative of additive, antagonistic and synergistic
effects, respectively. The results are displayed in Fig. 3 and are as
predicted above. At highmolar ratios (mF-8066 to NCCG-gp41 ratios of
30:1 and 1:10), the effects are essentially additive with CI values close
to 1. Maximum antagonism is observed at a molar ratio of mF-8066 to
NCCG-gp41 of 3:1 with a CI of ∼25. At intermediate molar ratios,
increasing antagonism (i.e. larger CI values) is observed as the molar
ratio approaches 3:1 of mF-8066 to NCCG-gp41.Breadth of neutralizing activity of Fabs 8060, 8066 and 8068 against a
Standard Reference Panel of subtype B and C strains
On the basis of the neutralization data obtained with laboratory-
adapted HIV-1 strains, further studies were conﬁned to the three
most potent Fabs, 8060, 8066 and 8068. The breadth of HIV-1
neutralization activity of the Fabs in both mono- and bivalent
formats was investigated using HIV pseudotyped with Envs from
the Standard Reference Panels of HIV-1 subtypes B (Mascola et al.,
2005) and C (Williamson et al., 2003) (Tables 3 and 4). A summary
of the results in the form of a comparison of neutralization activity
of the afﬁnity-matured Fabs to the parental Fab 3674 is presented in
Table 5.
For the parental Fab 3674, the bivalent format is 10–20-fold more
potent than the monovalent format in terms of neutralization
activity across the panel of HIV-1 B and C clades. The differential in
neutralization potency between bivalent and monovalent formats is
reduced to 2–5-fold for the afﬁnity-matured Fabs (Tables 3–4). Thus,
the afﬁnity-matured monovalent Fabs showed markedly improved
potency relative to the parental monovalent Fab, compared to their
bivalent counterparts. On average the IC50 value for the most potent
Fab, mF-8066, was reduced by over 5-fold, when compared to the
IC50 of the parental mF-3674 (average IC50mF-8066/IC50mF-3674 ratio of
0.17±0.1 and 0.16±0.1 for HIV-1 subtype B and C panels,
respectively), whereas the IC50 value for bF-8066 was only reduced
by about 2-fold (average IC50bF-8066/IC50bF-3674 ratio of 0.44±0.2 and
0.45±0.3 for HIV-1 subtype B and C panels, respectively). All of the
afﬁnity-matured monovalent Fabs neutralized all pseudoviruses of
the HIV-1 subtype B and C Env panels, which correspond to Tier2
contemporary primary isolates (Mascola et al., 2005). This is a
signiﬁcant improvement in breadth of neutralization, compared to
the parental mF-3674, which neutralized 92% of pseudoviruses from
the subtype B panel and only 67% of pseudoviruses from the subtype
C panel.
With regard to the afﬁnity-matured Fabs in bivalent format it is
interesting to note that while the neutralization activity against many
of the strains is only slightly better than that for the parental Fab bF-
3674, there are four B strains (TRJO4551.58, THRO41456.18,
WITO4160.33 and RHPA4259.7) and three C strains (ZM249M.PL1,
CAP45.2.00.G3 and ZM197M.PB7) for which improvements in
potency ranging from 5 to 50-fold are observed.
Table 3
Neutralization activity of monovalent and bivalent, afﬁnity-matured Fabs against primary isolates of subtype B HIV-1.
Env IC50 (nM)a
Monovalent Fabs Bivalent Fabs
mF-3674 mF-8068 mF-8060 mF-8066 bF-3674 bF-8068 bF-8060 bF-8066
Ac10.0.29 2000±680 520±300 450±290 340±110 120±47 130±91 35±25 85±34
WITO4160.33 1800±820 270±110 310±170 180±73 200±83 43±26 31±17 47±27
THRO4156.18 6800±2100 830±270 550±230 500±110 2000±470 340±77 370±96 210±31
CAAN5342.A2 2700±480 1000±360 580±170 450±83 340±51 290±58 210±67 220±45
PVO.4 NA 1200±690 2000±1100 1100±450 NA 450±200 310±160 210±58
TRO.11 2000±470 710±310 940±460 610±180 200±25 170±79 150±57 150±35
RHPA4259.7 3000±890 970±430 710±290 560±180 940±460 360±160 270±120 190±77
TRJO4551.58 990±410 540±320 460±260 300±100 1100±420 140±66 96±48 93±23
6535.3 9000±4000 430±230 740±220 540±170 550±190 280±110 310±89 280±77
REJO4541.67 5900±1500 3800±1500 2600±860 1400±190 2300±810 5200±4200 1200±400 1300±180
SC422661.8 2300±1100 1100±380 860±310 450±120 160±45 170±62 94±35 110±32
QH0692.42 7100±1900 770±270 850±380 700±240 2000±690 1800±720 1400±650 860±230
a NA, no activity. Neutralization activity was too weak to reliably determine an IC50.
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Using HXB2 Env-pseudotyped HIV infections that are synchro-
nized and temperature-arrested at the CD4-bound step, we measured
viral infectivity as a function of time of addition of fully inhibitory
concentrations of antibody (Gustchina et al., 2008). The results are
summarized in Table 6. We have previously shown that the
neutralizing activity of bF-3674 had a comparable half-life to that of
the C34 peptide, indicating that the two fusion inhibitors act at
approximately the same stage of the fusion process (Gustchina et al.,
2008). Although we were able to demonstrate that mF-3674 is able to
inhibit HIV infection at the same stage of the fusion process as C34, bF-
3674 and the afﬁnity-matured Fabs, a very high concentration
(approximately 5.5 μM) of mF-3674 was required to achieve such
inhibition. Within a reasonable concentration range (≤2 μM) mF-
3674 was essentially inactive post-CD4 engagement due to its poor
IC50 in the post-attachment neutralization assay (Table 6). At a
concentration of 2 μM the afﬁnity-matured Fabs neutralized HIV-1
infection post-CD4 engagement with essentially the same half-lives
(23–26 min) as C34 (Table 6), which may provide an explanation for
the marked increase in their neutralization potency.
Concluding remarks
Afﬁnity maturation of the broadly neutralizing Fab 3674 resulted
in the generation of a panel of Fabs with improved binding afﬁnity
(ranging from 4 to 12-fold) towards the target antigen, NCCG-gp41 a
chimeric construct that presents both the trimeric N-HR coiled-coil
and the 6-HB (Table 1). However, not all of the Fabs selected on theTable 4
Neutralization activity of monovalent and bivalent, afﬁnity-matured Fabs against primary i
Env IC50 (nM)a
Monovalent Fabs
mF-3674 mF-8068 mF-8060 mF
DU172.17 4900±2500 140±62 180±82 9
ZM214M.PL15 6500±1400 2200±760 1200±320 77
DU422.1 1300±450 240±96 240±69 17
ZM197M.PB7 NA 890±380 1700±720 64
ZM135M.PL10a NA 680±220 840±450 34
CAP210.2.00.E8 NA 490±190 560±230 31
CAP45.2.00.G3 NA 490±140 610±300 25
ZM249M.PL1 2900±1100 690±250 510±230 37
DU156.12 2500±1100 290±150 520±240 19
ZM109F.PB4 800±120 490±54 340±47 33
ZM53M.PB12 1000±310 280±91 450±180 24
ZM233M.PB6 430±210 90±42 120±64 7
a NA, no activity. Neutralization activity was too weak to reliably determine an IC50.basis of binding afﬁnity possessed improved HIV-1 neutralization
activity (Table 2). Thus higher binding afﬁnity to the target antigen
did not necessarily correlate with improved neutralization activity of
the Fabs in the Env-pseudotyped HIV neutralization assays, providing
evidence for the importance of kinetic restriction as a determinant of
neutralization activity (Steger and Root, 2006). However, for the three
Fabs (8060, 8066 and 8068) selected for further study on the basis of
their improved neutralization activity (Table 2), a marked decrease in
IC50 values against HIV pseudotyped with the Envs of Tier2 viruses
was observed (Tables 3–5). The improved neutralization potency was
on average more pronounced for the Fabs in monovalent than
bivalent format. This observation raises the question as to whether the
avidity advantage of the Fabs in bivalent format gives way to a
potential kinetic and/or steric advantage for the monovalent Fabs
once high afﬁnity binding has been achieved. In addition, the breadth
of neutralization activity of the monovalent Fabs was signiﬁcantly
enhanced (Tables 3–5). The monovalent Fabs mF-8060, mF-8066 and
mF-8068 showed neutralization activity against 100% of HIVs
pseudotyped with Tier2 Envs from the Standard Reference Panels of
subtypes B and C, whereas the parental monovalent Fab, mF-3674,
neutralized 92% of the panel B and only 67% of the panel C
pseudoviruses.
Materials and methods
gp41-derived proteins
Expression, puriﬁcation and folding of NCCG-gp41, N-terminal His-
tagged N35CCG-N13, N34CCG, and 6-HB were performed as describedsolates of subtype C HIV-1.
Bivalent Fabs
-8066 bF-3674 bF-8068 bF-8060 bF-8066
3±22 77±31 72±41 40±17 48±14
0±130 550±140 680±270 230±99 310±48
0±40 93±22 85±30 57±23 60±18
0±160 1900±660 410±210 280±110 300±110
0±110 340±92 380±120 200±80 150±45
0±88 450±120 150±55 110±33 83±25
0±110 500±260 78±53 53±32 53±33
0±76 3000±190 170±110 66±44 56±23
0±82 110±46 60±39 41±23 46±23
0±93 260±74 510±130 350±88 250±85
0±51 150±37 120±48 97±34 59±20
3±27 29±10 35±15 31±13 27±13
Table 5
Improvement in potency and breadth of neutralizing activity of afﬁnity-matured Fabs against diverse primary isolates from the standard subtype B and C reference panels.
Antibody Panel B Panel C
Average ratio of IC50s
relative to Fab 3674
Fold decrease in IC50s
relative to Fab 3674
Neutralization
breadth
Average ratio of IC50s
relative to Fab 3674
Fold decrease in IC50s
relative to Fab 3674
Neutralization
breadth
Monovalent
mF-3674 1 1 92 1 1 67
mF-8068 0.31±0.19 1.6–20.7 100 0.25±0.18 1.6–35.3 100
mF-8060 0.26±0.15 2.1–12.4 100 0.24±0.14 2.3–27.1 100
mF-8066 0.17±0.09 3.2–16.8 100 0.16±0.12 2.4–53.0 100
Bivalent
bF-3674 1 1 92 1 1 100
bF-8068 0.76±0.60 0.5–7.7 100 0.79±0.55 1.5–17.9 100
bF-8060 0.43±0.24 1.3–11.3 100 0.51±0.39 0.8–45.4 100
bF-8066 0.44±0.24 1.4–11.7 100 0.45±0.30 1.1–53.4 100
117E. Gustchina et al. / Virology 393 (2009) 112–119previously (Louis et al., 2001, 2003, 2005). (The His-tag comprises 20
residues.) NCCG-gp41 is a chimeric protein comprising N35CCG
(residues 546–580 of gp41 HIV-1 Env with Leu576, Gln577 and
Ala578 substituted by Cys, Cys and Gly, respectively) fused onto the
minimal thermostable ectodomain core of gp41 (Louis et al., 2001).
Thus, each chain of NCCG-gp41 comprises N35CCG–N34-(L6)-C28,
where N34 and C28 represent portions of the N-HR and C-HR regions
of gp41 (residues 546–579 and 628–655, respectively) and L6 is a six-
residue linker (SGGRGG). N35CCG-N13 is a 48 residue polypeptide that
comprises N35CCG immediately followed by N13 (residues 546–548)
(Louis et al., 2003). Three chains of NCCG-gp41, N35CCG-N13 and
N34CCG are linked covalently via three intermolecular disulﬁde
bridges. 6-HB is the minimal thermostable ectodomain core of gp41
comprising N34-(L6)-C28 (Tan et al., 1997). Single (m81-89) and
double (m90-m97) alanine mutants of His-tagged 6-HB involving
surface exposed residues of the N-HR that lie in a shallow groove
between two C-HR helices were as follows (Gustchina et al., 2007):
m81, Q550A; m82, N553A; m83, R557A; m84, E560A; m85, H564A;
m86, Q576A; m87, W571A; m88, K574A; m89, Q575A; m90, Q550A/
N553A; m91, N553A/R557A; m92, R557A/E560A; m93, E560A/
H564A; m94, H564A/Q567A; m95, Q567A/W571A; m96, W571A/
K574A; and m97, K574A/Q575A. C-terminal His-tagged 5-helix (Root
et al., 2001) was expressed and puriﬁed as described previously
(Gustchina et al., 2007). All proteins underwent a ﬁnal puriﬁcation
step using size exclusion chromatography and were characterized by
gel electrophoresis and ES-MS.
Afﬁnity maturation of Fab 3674 by exchange of the CDR-H2 loop
DNA encoding Fab 3674 was subcloned from an expression vector
into a phagemid vector based on pMorph23 (US Patent 6,753,136).
The heavy chain CDR-H2 sequence was removed by restriction digest
and a repertoire of CDR-H2 sequences was cloned into this construct.
The CDR-H2 repertoire was designed according to the respective
amino acid distribution at each position of naturally occurring, humanTable 6
Comparison of pre-attachment (regular assay) and post-attachment (following CD4
engagement) HIV-1 HXB2 neutralization activity together with the half-lives of the
inhibitor-sensitive state obtained from assays synchronized at the CD4-bound step.
Fusion
inhibitor
Pre-attachment
IC50 (nM)
Post-attachment
IC50 (nM)
Half-life of inhibitor-sensitive
state (min)
bF-3674 42±12 85±11 24±2
mF-3674 630±160 1600±320 24±2
mF-8068 160±72 820±68 26±3
mF-8060 130±30 480±110 24±1
mF-8066 82±29 400±61 23±2
C34a 6±2 4±0.4 23±1
a C34 is a peptide fusion inhibitor derived from the C-HR of gp41 that targets the N-
HR of gp41 (Chan et al., 1998).rearranged antibody genes using trinucleotides for gene synthesis
(Virnekas et al., 1994; Knappik et al., 2000; Rothe et al., 2008).
Electroporation into Escherichia coli Top10F' competent cells (Invitro-
gen) resulted in a library of about 1.3×106 antibodies with different
heavy chain CDR-H2 loops.
Two rounds of panning were performed on NCCG-gp41 coupled
magnetic beads (M-450 Epoxy, Invitrogen) applying increased
washing stringency compared to the standard panning conditions
used for selection of the parental Fab 3674 (Gustchina et al., 2007).
After the second round of panning, the enriched pool of Fab genes was
subcloned into the expression vector pMORPHx9_Fab-MH for the
expression of myc-his6 tagged monovalent Fab fragments (Rauchen-
berger et al., 2003). E. coli TG1F− (TG1 without the F plasmid) was
transformed with the ligation mixture and plated. 384 colonies were
randomly picked and transferred to a 384-well microtiter plate. Then
368 clones were tested for binding to NCCG-gp41 coupled beads by
FLISA on a CDS8200 instrument (Applied Biosystems). Brieﬂy, NCCG-
gp41 coupled beads, Fab containing E. coli lysates and ﬂuorescence-
labeled anti-human Fab secondary antibody were mixed and
incubated for 1 h. Fluorescence on beads settled at the bottom of
the wells indicated positive lysates. More than 200 hits were obtained
in the primary screening. The 10 clones with the best signal and in
addition 10 clones selected at randomwere sequenced and 12 unique
antibodies were found. These were expressed and puriﬁed via the his6
tag by afﬁnity chromatography. Speciﬁc binding to NCCG-gp41 was
conﬁrmed by ELISA and the 10 antibodies with the highest signal on
NCCG-gp41were selected for further characterization. These Fabswere
also subcloned and expressed in the bivalent Fab-dHLX-MH format
(Jarutat et al., 2006; Gustchina et al., 2007). Composition and purity of
antibodies were conﬁrmed by SDS-PAGE, and Western blot analysis
against the panel of gp41 ectodomain-derived constructs was carried
out as described previously (Gustchina et al., 2007).
Determination of Fab afﬁnities for NCCG-gp41 using Solution Equilibrium
Titration (SET)
Electrochemiluminescence (ECL) based afﬁnity determination by
solution equilibrium titration was performed essentially as described
previously (Haenel et al., 2005; Steidl et al., 2008).
Cell lines and molecular clones
The HIV-1 expression plasmid SG3Δenv (catalog no. 11051), the
Standard Reference Panel of subtype B HIV-1 Env clones (catalog no.
11227), the Standard Reference Panel of subtype C HIV-1 Env clones
(catalog no. 11326), the HIV-1 Env molecular clone pCAGGS SF162
gp160 (catalog no. 10463), the Murine leukemia virus (MuLV) Env
clone SV-A-MLV-env (catalog no. 1065), the vesicular stomatitis virus
(VSV) G glycoprotein clone pHEF-VSVG (catalog no. 4693), and
indicator cells TZM-b1 (or JC53BL-13, catalog no. 8129) were obtained
118 E. Gustchina et al. / Virology 393 (2009) 112–119from the National Institutes of Health AIDS Research and Reference
Reagent Program. 293T cells were obtained from the American Type
Culture Collection. gp160 expression plasmids pSVIII HBXc2, 89.6 and
JR CSF were provided by Dr. J.Sodroski, Department of Cancer
Immunology and AIDS, Dana-Farber Cancer Institute (Sullivan et al.,
1995; Karlsson et al., 1996), and the NL4-3 gp160 expression plasmid
pHenv was provided by Dr. E. Freed, HIV Drug Resistance Program,
NCI (Freed et al., 1989). gp160 expression plasmids pSVIII BaL01 and
BaL26 (Li et al., 2005, 2006) were provided by Dr. J. Mascola, BSL-3
Core Virology Laboratory, Vaccine Research Center, NIAID.
Env-pseudotyped HIV-1 preparation
Env-pseudotyped HIV-1 stocks were prepared essentially as
described (Li et al., 2005, 2006; Gustchina et al., 2007). Exponentially
dividing 293T cells were cotransfected using FUGENE6 transfection kit
(Roche, Nutley, NJ) with the Env-deﬁcient HIV-1 expression plasmid
SG3Δenv and an Env-expressing plasmid in ratios proportional to
their individual sizes (∼16 μg total DNA per 50 to 80% conﬂuent T-150
culture ﬂask). Culture supernatants were collected 2 days post-
transfection, ﬁltered through 0.45 μm ﬁlter, and stored at −80 °C.
HIV-1 neutralization assay
Env-pseudotyped HIV neutralization assays were performed
essentially as described (Li et al., 2005, 2006; Gustchina et al.,
2007). Serial dilutions of Fabs in phosphate buffer saline (10 μl) were
added to Env-pseudotyped virus (in 40 μl Dulbecco's modiﬁed Eagle
medium plus 10% fetal calf serum), followed by the addition of freshly
trypsinized TZM-bl indicator cells (JC53BL-13), a HeLa-derived cell
line genetically modiﬁed to constitutively express CD4, CCR5, and
CXCR4 (10,000 cells in 20 μL of the samemedium). After incubation at
37 °C overnight, 150 μL of fresh growth medium was added.
Approximately 48 h post-infection cells were lysed and luciferase
activity was measured using the BrightGlo luciferase assay kit
(Promega, Madison, WI) with a Synergy2 luminescence microplate
reader (BioTek Instruments, Inc., Winooski, VT). Pseudovirus stocks
were diluted to yield approximately 200 to 1000-fold increase of
luminescence for an infected control over the uninfected control. IC50
values were obtained by a non-linear least-squares ﬁt of a simple
dose–activity relationship, given by % infection=100/(1+[Fab]/
IC50), to the experimental data.
Analysis of neutralizing activity of mF-8066 in combination with
NCCG-gp41
The neutralizing activity of multiple constant-ratio combinations
of mF-8066 antibody and NCCG-gp41 protein was tested in serial
dilutions in HXB2 Env-pseudotyped HIV neutralization assays. The
data were analyzed as described previously (Gustchina et al., 2006).
Post-attachment HIV-1 neutralization assay
The neutralizing activity of Fabs after attachment of pseudovirus to
the target cells following CD4 engagement wasmeasured as described
previously (Gustchina et al., 2008).
Synchronized and “time-of-addition” Env-pseudotyped HIV
neutralization assay
Synchronized viral infection assays in the context of the HXB2 Env-
pseudotyped virus neutralization assay were performed using the
spinoculation technique (O'Doherty et al., 2000; Reeves et al., 2002)
as described previously (Gustchina et al., 2008). The infectivity (y) as
a function of the time post-infection (t) of addition of the Fabs was ﬁt
to a sigmoidal function given by y = ymax = ½1 + e t1 = 2− tð Þ=k wheret1/2 is the half-life of the inhibitor-sensitive state of Env and k is a
constant that determines the shape of the sigmoidal curve (Reeves
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